The Challenge of Translating Mexican Medical Innovations
For too long, numerous innovations in Mexico have remained confined to university laboratories, with researchers publishing scientific articles but failing to translate their groundbreaking ideas into tangible medical solutions for patients. This has led to Mexico relying heavily on imported medical innovations from abroad.
Introducing Booster 2025: An Opportunity for Mexican Medical Innovations
In response to this reality, initiatives like the recent call launched by Fundación INCIDE in collaboration with Chilean consultancy New Genesis and eight Mexican pharmaceutical companies are gaining traction. This program, named Booster 2025, aims to select promising ideas from researchers and support them in becoming viable medical projects.
What is Booster 2025?
Booster 2025 is an intensive eight-week program offering over 150 hours of mentorship in areas such as technology validation, regulation, intellectual property, business models, and capital raising. The program’s goal is to help promising projects bypass clinical trials, secure crucial funding, and scale up for industrial production.
Who can participate in Booster 2025?
- Universities
- Research centers
- Startups
- Scientific and technology-based companies (EBCT)
What support does Booster 2025 offer?
The program provides access to more than 60 certified facilities, over $1 billion in R&D investment, and international marketing networks. The initiative culminates in a ‘Demo Day’ on October 13, where participants present their projects to investors and strategic partners, opening doors to both national and international markets.
How does Booster 2025 align with Mexico’s health goals?
Booster 2025 supports President Claudia Sheinbaum’s Plan México, which aims to attract $2 billion annually in clinical research, increase medical supply production by 15%, and manufacture vaccines and biosimilars in Mexico. This initiative not only advances scientific progress but also serves as an economic engine, generating jobs, national wealth, and competitiveness.
Success Stories: Neolpharma and UNAM’s Collaboration
Diego Ocampo Gutiérrez de Velasco, president of Fundación INCIDE and vicepresident of technology for Grupo Neolpharma, shared an inspiring example: the first licensing agreement between Neolpharma and UNAM for a therapeutic molecule. After seven years of collaboration with the Institute of Medical Research and Cancer (InCan), a combination of drugs for treating a specific cancer type was integrated into national therapeutic guidelines.
Key Questions and Answers
- What is Booster 2025? An intensive eight-week program offering mentorship in various aspects of medical innovation to help promising projects become viable solutions.
- Who can participate? Universities, research centers, startups, and scientific and technology-based companies (EBCT).
- What support does Booster 2025 offer? Access to certified facilities, R&D investment, international marketing networks, and a ‘Demo Day’ for presenting projects to investors.
- How does Booster 2025 align with Mexico’s health goals? It supports clinical research attraction, medical supply production increase, and local vaccine/biosimilar manufacturing, driving scientific progress and economic growth.
